Tibor Attila Rauch

US Patent:

8399193, Mar 19, 2013

Filed:

Aug 29, 2008

Appl. No.:

12/231337

Inventors:

Gerd P. Pfeifer - Duarte CA, US
Tibor A. Rauch - Chicago IL, US
Zunde Wang - San Gabriel CA, US
Xiwei Wu - Duarte CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 1/68

US Classification:

435 611

Abstract:

The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e. g. , a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e. g. , squamous cell carcinomas and adenocarcinomas.

US Patent:

20060240460, Oct 26, 2006

Filed:

Apr 6, 2006

Appl. No.:

11/398765

Inventors:

Gerd Pfeifer - Bradbury CA, US
Tibor Rauch - Arcadia CA, US

Assignee:

City of Hope - Duarte CA

International Classification:

C12Q 1/68
C12P 19/34

US Classification:

435006000, 435091200

Abstract:

The present invention provides new and improved assay for detection of genomic methylated CpG islands. This new method is termed the methylated-CpG island recovery assay (MIRA). In accordance with one embodiment, MIRA comprises the steps of: (a) incubating genomic DNA fragments with a methylated CpG island binding protein in the presence of a binding partner for the binding protein to produce bound DNA containing methylated CpG islands, (b) isolating the bound DNA, and (c) detecting CpG island methylation by gene-specific amplification reactions. In accordance with a preferred embodiment, MIRA comprises the steps of: (a) incubating sonicated genomic DNA with a matrix containing a fusion protein of glutathione S-transferase (GST) and MBD2b (GST-MBD2b) in the presence of MBD3L1 to produce bound DNA containing methylated CpG islands, (b) eluting bound DNA from the matrix, and (c) detecting CpG island methylation by gene-specific amplification reactions.

US Patent:

20110301050, Dec 8, 2011

Filed:

Mar 22, 2011

Appl. No.:

13/069128

Inventors:

GERD P. PFEIFER - Bradbury CA, US
XIWEI WU - Diamond Bar CA, US
TIBOR A. RAUCH - Chicago IL, US

International Classification:

C40B 30/04
C07H 21/04
C12Q 1/68

US Classification:

506 9, 435 611, 536 235

Abstract:

One aspect of the present disclosure relates to a composition comprising a DNA hypermethylation brain cancer marker on acellular DNA of a human subject. DNA hypermethylation brain cancer markers (or DNA hypermethylation markers) are frequently methylated in the DNA of brain cells and acellular DNA of individuals suffering from brain cancer. These DNA hypermethylation markers are not frequently methylated in the DNA of brain cells and acellular DNA of individuals who do not suffer from brain cancer. Another aspect of the present disclosure relates to a method of diagnosing brain cancer in a human subject comprising providing a sample containing acellular DNA from the human subject, determining whether one or more DNA hypermethylation markers on the acellular DNA are hypermethylated, and diagnosing brain cancer when the DNA hypermethylation markers are hypermethylated.

US Patent:

20130116147, May 9, 2013

Filed:

Jan 10, 2013

Appl. No.:

13/738869

Inventors:

CITY OF HOPE - Duarte CA, US
Tibor A. RAUCH - Chicago IL, US
Zunde WANG - San Gabriel CA, US
Xiwei WU - Duarte CA, US

Assignee:

CITY OF HOPE - Duarte CA

International Classification:

C12Q 1/68

US Classification:

506 9, 435 611

Abstract:

The present invention relates to the identification of novel DNA biomarkers and the use of the aberrant methylation patterns of the biomarkers to diagnose a disease or a condition (e.g., a cancer) associated therewith. In particular, the present invention relates to the use of the novel DNA biomarkers to diagnose lung cancers, e.g., squamous cell carcinomas and adenocarcinomas.